Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AC 699

Next Previous
Drug Profile

AC 699

Alternative Names: AC-0699; AC-699

Latest Information Update: 28 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Accutar Biotechnology
  • Class Antineoplastics
  • Mechanism of Action Estrogen receptor degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported HER2 negative breast cancer

Most Recent Events

  • 28 Jan 2026 No recent reports of development identified for phase-I development in HER2-negative-breast-cancer(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
  • 10 Dec 2024 Updated efficacy, pharmacodynamics and adverse events data from a phase I trial in HER2-negative-breast-cancer presented at the 47th Annual San Antonio Breast Cancer Symposium (SABCS-2024) .
  • 13 Sep 2024 Updated adverse events and pharmacokinetics data from a phase I trial in HER2-negative breast cancer presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top